Basel-based Novartis said the study was the first large controlled trial to show overall survival benefit in FLT3-mutated AML, and that worldwide regulatory submissions for midostaurin would begin in 2016.

 

(Reporting by Joshua Franklin; Editing by Kevin Liffey)

Source: Reuters Health

http://www.reuters.com/article/us-novartis-drugs-idUSKBN0TP0KW20151206#EuvRFFEUXltopEB8.97